[123I] β-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease

Neurology

Volumn 46, Issue 1, 1996, Pages 231-237

  Marek, K L ^a   Seibyl, J P ^a   Zoghbi, S S ^a   Zea Ponce, Y ^a   Baldwin, R M ^a   Fussell, B ^a   Charney, D S ^a   Van Dyck, C ^a   Hoffer, P B ^a   Innis, R B ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; DOPAMINE METABOLISM; DOPAMINERGIC TRANSMISSION; FEMALE; HUMAN; MALE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; CELL COUNT; CORPUS STRIATUM; METABOLISM; MIDDLE AGED; PATHOLOGY; SCINTISCANNING;

CARRIER PROTEIN; CITALOPRAM; DIAGNOSTIC AGENT; DOPAMINE TRANSPORTER; MEMBRANE PROTEIN; NERVE PROTEIN; RADIOACTIVE IODINE;

ADULT; AGED; CARRIER PROTEINS; CELL COUNT; CITALOPRAM; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; PARKINSON DISEASE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0029664364     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.46.1.231     Document Type: Article

References (42)

1. Koller WC, Langston JW, Hubble JP, et al. Does a long preclinical period occur in Parkinson's disease. Neurology 1991; 41(suppl 2):8-13.
2. McGeer PL, Itagaki S, Akiyama S, McGeer EG. Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 1988;24:574-576.
3. Golbe L. The genetics of Parkinson's disease: a reconsideration. Neurology 1990;40:7-16.
4. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitleberger F. Brain dopamine and the syndromes of Parkinson and Huntington, clinical, morphological, and neurochemical correlates. J Neurol Sci 1973;20:415-455.
5. Lees AJ. When did Ray Kennedy's Parkinson's disease begin? Mov Disord 1992;7:110-116.
6. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
7. Hart TS. Paralysis agitans: some clinical observations based on the study of 219 cases at the clinic of Professor M. Allen Starr. J Nerv Ment Dis 1904;31:177.
8. Watts RL, Mandir AS, Ahn KJ, Juncos JL, Zakers GO, Freeman A. Electrophysiologic analysis of early Parkinson's disease. Neurology 1991;41(suppl 2):44-48.
9. Nahmias C, Garnett ES, Firnau G, Lang A. Striatal dopamine distribution in parkinsonian patients during life. J Neurol Sci 1985;69:223-230.
10. 18F-Dopa uptake: difference in Parkinson's disease and atypical parkinsonism. J Neurol Neurosurg Psychiatry 1991;54:898-904.
11. 18F-Dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990; 28:547-555.
12. Sawle GV. The detection of preclinical Parkinson's disease: what is the role of positron emission tomography? Mov Disord 1993;8:271-277.
13. Snow BJ, Peppard RF, Guttman M, Calne DB. Positron emission tomographic scanning demonstrates a presynaptic dopaminergic lesion in Lytico-Bodig. Arch Neurol 1990;47:870-874.
14. Calne DB, Langston JW, Martin WRW, et al. Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease. Nature 1985;317:246-248.
15. 18F-DOPA and positron emission tomography. Neurology 1992;42:1894-1900.
16. Uhl GR. Neurotransmitter transporters (plus): a promising new gene family. Trends Neurosci 1992;15:265-268.
17. Leenders K, Salmon EP, Tyrrell P, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990;47:1290-1298.
18. 123I]-2-β-Carbomethoxy-3-β-(4-iodophenyl)-tropane (β-CIT): high affinity SPECT radiotracer of monoamine reuptake sites in brain. J Med Chem 1991;34:3144-3146.
19. Kaufman MJ, Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's diseased striatum. Synapse 1991;9:43-49.
20. Shaya EK, Scheffel U, Dannals RF, et al. In vivo imaging of dopamine reuptake sites in the primate brain using single photon emission computed tomography (SPECT) and iodine-123 labeled RTI-55. Synapse 1992;10:169-172.
21. 11C-WIN 35,428 reveals marked decline in mild Parkinson's disease. Ann Neurol 1993;34:423-431.
22. Innis RB, Seibyl JP, Scanley BE, et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci USA 1993;90:11965-11969.
23. 121I]β-CIT and SPECT correlates with clinical findings [abstract]. Mov Disord 1994;9(suppl 1):120.
24. 123I] β-CIT SPECT imaging in idiopathic parkinson's disease: correlation of striatal binding abnormality with disease severity [abstract]. Mov Disord 1994;9(suppl 1):89.
25. Fahn S, Elton RL. Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent developments in Parkinson's disease. Florham Park, NJ: Macmillan Healthcare Information, 1987:153-164.
26. Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 1992;7:2-13.
27. 123I]β-CIT) in nonhuman primates: pharmacokinetics, biodistribution, and SPECT brain imaging coregistered with MRI. Nucl Med Biol 1993;20:597-606.
28. Holman BL, Carvalho PA, Zimmerman RE, et al. Brain perfusion SPECT using an annular single crystal camera: initial clinical experience. J Nucl Med 1990;31:1456-1461.
29. Chang LT. A method for attenuation correction in computed tomography. IEEE Trans Nucl Sci 1987;25:638-643.
30. 123I]β-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 1994;14:982-994.
31. Fang J, Yu PH. Effect of L-deprenyl, its structural analogues and some mono-amine oxidase inhibitors on dopamine uptake. Neuropharmacology 1994;33:763-768.
32. 123I]β-CIT SPECT. J Nucl Med (in press).
33. Volkow ND, Fowler JS, Wang GJ, et al. Decreased dopamine transporters with age in healthy human subjects. Ann Neurol 1994;36:237-239.
34. Vingerhoets FJG, Snow BJ, Lee CS, Schulzer M, Mak E, Calne DB. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol 1994;36:759-764.
35. Scherman D, Desnons C, Darchen F, Pollak P, Javoy-Agid F, Agid Y. Striatal dopamine deficiency in Parkinson's disease: role of aging. Ann Neurol 1989;26:551-557.
36. Sawle GV, Colebatch JG, Shah A, Brooks DJ, Marsden CD, Frackowiak RJS. Striatal function in normal aging - implications for Parkinson's disease. Ann Neurol 1990;28:799-804.
37. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the stratum of patients with idiopathic Parkinson's disease. N Engl J Med 1988;318:876-880.
38. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301.
39. Calne DB. Is idiopathic parkinsonism the consequence of an event or a process? Neurology 1993;44:5-10.
40. Lee CS, Schulzer M, Mak EK, et al. Clinical observations on the rate of progression of idiopathic parkinsonism. Brain 1994;117:501-507.
41. Eidelberg D, Moeller JR, Dhawan V, et al. The metabolic anatomy of Parkinson's disease complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies. Mov Disord 1990;5:203-213.
42. Brooks DJ. Functional imaging in relation to parkinsonian syndromes. J Neurol Sci 1993;115:1-17.